Ecovia Bio Secures Series B Funding for Biopolymer Development
Some companies talk sustainability like it is a vibe. Ecovia Bio treats it like an engineering problem that does not care about your feelings. Founded in 2014 and built in Michigan, this is fermentation science with steel-toed boots on, turning gamma polyglutamic acid into something the market can actually scale, ship, certify, and sell without crossing fingers or apologizing to regulators.
The Series B just closed with Pointe Angels leading, and yes, the dollar figure stays quiet, which is fine. Real builders know the number that matters is capacity. Under the leadership of Kousay Said, CEO, with Dr. Jeremy Minty, Co-founder and CTO, driving the technology and Dr. Xiaoxia “Nina” Lin, Co-founder and Scientific Advisor, anchoring the science, Ecovia Bio is expanding manufacturing in Livonia, Michigan, inside a commissioned 20,000 sq ft facility that already carries a heavy statement. First and only manufacturer of polyglutamic acid and its derivatives in the U.S. is not marketing poetry. It is an operational flex.
Gamma polyglutamic acid, or PGA, is not new science. What is new is making it behave at industrial scale without turning into a lab curiosity. AzuraBase comes in clean and linear, water-soluble, 100% bio-based, typically around 500k Da, built for applications that want performance without petrochemical baggage. AzuraGel goes further, crosslinked and thirsty, absorbing up to 300x its weight in water, holding up under load where starch taps out. USDA Certified 100% bio-based. OECD 301B ready biodegradable with 92.7% degradation in 28 days. When compared head to head in aqueous aerobic testing, 90.2% degradation in 56 days while a market-leading polyacrylic acid SAP limps in at 4.5%. Numbers like that do not need a hype man.
This is why the demand signal spans cosmetics, personal care, agriculture, hygiene, packaging gels, and water treatment. Performance sells first. Sustainability closes the deal. Geoff Horst, CIO, and the innovation team understand that buyers do not want sermons. They want materials that behave better, last as long as needed, then leave without a mess. The Series B is about pushing that promise through expanded production, hitting full operational capacity by 2028, and already thinking beyond it.
There is a quiet lesson here for founders watching from the sidelines. Fermentation is patient capital. Certifications beat slogans. Domestic manufacturing still matters. And when a material like PGA finally finds its moment, the companies that win are the ones who invested early in process, people, and proof, then let the results do the talking while the rest of the market starts asking how fast supply can actually show up.